Biomet U.S. Hip Sales Advance 14% In Q1; Spine Revenues “Essentially Flat”
This article was originally published in The Gray Sheet
Executive Summary
Biomet's accelerated U.S. hip sales growth of 14% for its most recent fiscal quarter is attributable in part to difficulties facing its competitors, as well as the strength of products like its Taperloc hip system, M2a-Magnum acetabular system and E-Poly acetabular liners, according to the company